EMA told to broaden access to ADRs
This article was originally published in Scrip
The European Ombudsman has asked the European Medicines Agency to review its transparency policy so that the public may have access to suspected serious drug adverse reaction reports, regardless of the form in which they are held. The EMA has until 31 July to submit a response to the ombudsman, who investigates complaints about maladministration in European Union institutions or bodies.
You may also be interested in...
Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’
Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.